Nirogacestat hydrobromide in AIDS-related Kaposi Sarcoma: NCT07539454 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
28
Planned enrollment
2030-02-17
Primary-completion proxy
Executive view
NCT07539454 evaluates Nirogacestat hydrobromide in AIDS-related Kaposi Sarcoma. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Overall response rate (ORR), assessed over Up to 5 years after completion of study treatment.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07539454 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider AIDS-related Kaposi Sarcoma landscape. Drug & Asset MCP drug_fetch was queried for Nirogacestat hydrobromide, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07539454 | Nirogacestat hydrobromide | Phase 2 / Not yet recruiting | Sponsor not reported | United States | Overall response rate (ORR) Up to 5 years after completion of study treatment | 2030-02-17 |
| NCT07695311 | Pembrolizumab | Phase 1 / Not yet recruiting | The Case Comprehensive Cancer Center | United States | Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events Up to 6 months | 2029-10-01 |
| NCT07658768 | Indocyanine Green | Early Phase 1 / Not yet recruiting | Abramson Cancer Center | Geography not reported | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) 1 year | 2027-05-01 |
| NCT07648069 | Sintilimab | Phase 1 / Recruiting | Sun Yat-Sen University | China | Incidence and severity of adverse events 120 days | 2026-12-31 |
| NCT07633756 | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang ) | Phase 1 / Recruiting | M.D. Anderson International España SA | United States | Safety and adverse events (AEs). Through study completion; an average of 1 year | 2029-12-26 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07539454 is a Phase 2, not yet recruiting study with 28 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Overall response rate (ORR)” over “Up to 5 years after completion of study treatment.” The retrieved endpoint description is: The ORR will be estimated for each dose group and for all groups combined. The 95% confidence intervals will be constructed for the ORR..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 28 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for AIDS-related Kaposi Sarcoma. These records do not establish direct evidence for NCT07539454 unless the registration number matches.
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Ace…
Phase 3; n=1016; ARR(Mean) = 0.182 Relapses per participant per year (Standard Error, 0.022); ARR(Mean) = 0.260 Relapses per participant per year (Standard Error, 0.029) Source: https://clinicaltrials.gov/ct2/show/results/NCT04121221
Real-world efficacy of fixed-dose weekly paclitaxel for AIDS-associated Kaposi Sarcoma: a 16-year cohort study in Rio de Janeiro, Brazil
Not Applicable; n=176; CR = 58.0 % Source: https://programme.aids2026.org/Abstract/Abstract/?abstractid=10933
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Angiosarcoma
Phase 2; n=6; Progression-free Rate at 9 Cycles = 67 Percentage of participants (95% Confidence Interval, 20 - 90) Source: https://clinicaltrials.gov/ct2/show/results/NCT05026736
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Nirogacestat hydrobromide.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Nirogacestat hydrobromide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07539454
Protocol source: https://clinicaltrials.gov/study/NCT07539454
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Nirogacestat hydrobromide in AIDS-related Kaposi Sarcoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Overall response rate (ORR) and 2030-02-17 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
